Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 135

Sort by

Sort Order Select

Journal Articles

Preliminary Results of a Phase 1 Dose Escalation Study of the First-in-Class IgM Based Bispecific Antibody Igm-2323 (anti-CD20 x anti-CD3) in Patients with Advanced B-Cell Malignancies

Elizabeth Budde, MDPhD, Ajay K. Gopal, MD, Ian W. Flinn, MD PhD, Loretta J. Nastoupil, MD, Michael S. Gordon, MD, Ching-Fai Pang, PhD, Bruce Keyt, PhD, Steve Carroll, PhD, Maya Leabman, PhD, Genevive Hernandez, PhD, Iris Sison, Daniel Chen, MD PhD, Wayne Godfrey, MD, Philippe Armand, MD PhD

Blood (2020) 136 (Supplement 1): 45–46.

https://doi.org/10.1182/blood-2020-134983

Published: 2020

Journal Articles

Pembrolizumab with R-CHOP in Previously Untreated Diffuse Large B-Cell Lymphoma: Long Term Follow up and Analysis of the Mechanism of Pdl-1 Tumor Expression

Stephen D. Smith, MD, Jonathan R. Fromm, MD PhD, Min Fang, MD PhD, Brian G. Till, MD, Mazyar Shadman, MDMPH, Ryan C. Lynch, MD, Andrew J. Cowan, MD, Qian Vicky Wu, PhD, Jenna Voutsinas, MPH, Heather A. Rasmussen, BS, Katie Blue, Chaitra S. Ujjani, MD, Andrei R Shustov, MD, Ryan D. Cassaday, MD, Ajay K. Gopal, MD

Blood (2020) 136 (Supplement 1): 13–14.

https://doi.org/10.1182/blood-2020-137328

Published: 2020

Journal Articles

Ibrutinib and Venetoclax in Relapsed and Refractory Follicular Lymphoma

Blood (2020) 136 (Supplement 1): 46–47.

https://doi.org/10.1182/blood-2020-136219

Published: 2020

Journal Articles

Predictors of Cytopenia after Treatment with Axicabtagene Ciloleucel in Patients with Large Cell Lymphoma

Lorena Panaite, MBBS, Jordan Gauthier, MD, Paula Perkins, MS,PA-C, Jenna Voutsinas, MPH, Qian Vicky Wu, PhD, Angela Kirk, PA-C, Aisling Cearley, PA-C, Erin Mullane, DNP, Ryan D. Cassaday, MD, Hans-Peter Kiem, MDPhD, Victor A. Chow, MD, Ryan C. Lynch, MD, Chaitra S. Ujjani, MD, Stephen D. Smith, MD, Ajay K. Gopal, MD, Brian G. Till, MD, Cameron J. Turtle, MBBS, PhD, David G. Maloney, MD PhD, Mazyar Shadman, MDMPH

Blood (2020) 136 (Supplement 1): 1–2.

https://doi.org/10.1182/blood-2020-134816

Published: 2020

Journal Articles

Dose-Dense Brentuximab Vedotin Plus Ifosfamide, Carboplatin, and Etoposide (ICE) Is Highly Active for Second Line Treatment in Relapsed/Refractory Classical Hodgkin Lymphoma: Final Results of a Phase I/II Study

Blood (2020) 136 (Supplement 1): 16–18.

https://doi.org/10.1182/blood-2020-133763

Published: 2020

Journal Articles

Ixazomib-Rituximab in Untreated Indolent B-NHL: An Effective, Very Low Toxicity Regimen

Solomon A. Graf, MD, Ryan C. Lynch, MD, Ted A Gooley, PhD, Chaitra S. Ujjani, MD, Peter Wilcox, Sabrina Wilcox, David G. Coffey, MD, Andrew J. Cowan, MD, Stephen D. Smith, MD, Mazyar Shadman, MDMPH, Edus H. Warren, MD PhD, Edward Libby, MD, Colin D. Godwin, MDMPhil, Ryan D. Cassaday, MD, Jonathan R. Fromm, MD PhD, Ajay K. Gopal, MD

Blood (2020) 136 (Supplement 1): 4.

https://doi.org/10.1182/blood-2020-137226

Published: 2020

Journal Articles

Third Generation CD20 Targeted CAR T-Cell Therapy (MB-106) for Treatment of Patients with Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma

Blood (2020) 136 (Supplement 1): 38–39.

https://doi.org/10.1182/blood-2020-136440

Published: 2020

Journal Articles

Low Achievement of End of Life Quality Measures in Large B-Cell Lymphoma Patients Who Progressed after CD19-Specific CAR-T Cell Therapy

Ryan C. Lynch, MD, Victor A. Chow, MD, David G. Maloney, MD PhD, Cameron J. Turtle, MBBS, PhD, Mazyar Shadman, MD, Chaitra S. Ujjani, MD, Ryan D. Cassaday, MD, Brian G. Till, MD, Yolanda D. Tseng, MD, Edus H. Warren, MD PhD, Andrei R Shustov, MD, Manoj P. Menon, MD, Elizabeth Loggers, MD PhD, Jenna M. Voutsinas, MPH, Ted Gooley, PhD, Ajay K. Gopal, MD, Stephen D. Smith, MD

Blood (2019) 134 (Supplement_1): 413.

https://doi.org/10.1182/blood-2019-124857

Published: 2019

Journal Articles

Ibrutinib in Relapsed or Refractory Transformed Indolent B-Cell Non-Hodgkin Lymphoma: Final Results from a Prospective Phase II Study

Solomon A. Graf, MD, Ryan D. Cassaday, MD, Karolyn K. Morris, BA, Sanaz Behnia, MD, Qian Vicky Wu, PhD, Jenna M. Voutsinas, MPH, Ryan C. Lynch, MD, Elizabeth Krakow, MD, Heather A. Rasmussen, BS, Thomas R. Chauncey, MD PhD, Sandra Kanan, MSN, ARNP, Lorinda A. Soma, MD, Stephen D. Smith, MD, Ajay K. Gopal, MD

Blood (2019) 134 (Supplement_1): 1596.

https://doi.org/10.1182/blood-2019-126086

Published: 2019

Journal Articles

Diffuse Large B-Cell Lymphoma Is Infiltrated with Functional CD8 + T-Cells Lacking the Hallmarks of Exhaustion

Adam Greenbaum, MD PhD, Ajay K. Gopal, MD, Jonathan R. Fromm, MD PhD, A McGarry Houghton, MD

Blood (2019) 134 (Supplement_1): 1518.

https://doi.org/10.1182/blood-2019-126217

Published: 2019

Journal Articles

Impact of Lab Abnormalities at the Time of Progression in Patients Receiving CD19-Specific CAR T-Cell Therapy for Relapsed/Refractory Large B-Cell Lymphomas

Ryan C. Lynch, MD, Victor A. Chow, MD, David G. Maloney, MD PhD, Cameron J. Turtle, MBBS, PhD, Stephen D. Smith, MD, Mazyar Shadman, MD, Chaitra S. Ujjani, MD, Ryan D. Cassaday, MD, Brian G. Till, MD, Yolanda D. Tseng, MD, Edus H. Warren, MD PhD, Andrei R Shustov, MD, Manoj P. Menon, MD, Jenna M. Voutsinas, MPH, Ted Gooley, PhD, Ajay K. Gopal, MD

Blood (2019) 134 (Supplement_1): 2889.

https://doi.org/10.1182/blood-2019-124962

Published: 2019

Journal Articles

AG-636 for the Treatment of Adults with Advanced Lymphoma: Initiation of a Phase 1 Clinical Study

Scott F. Huntington, MD MPH, Avyakta Kallam, MD, Frank G. Basile, MD, Danielle Ulanet, Huansheng Xu, PhD, Feng Yin, PhD, Michelle Mobilia, BS, Michael Cooper, MD, Bijal Shah, MD, John P. Leonard, MD, Gottfried R. von Keudell, MD PhD, Ajay K. Gopal, MD

Blood (2019) 134 (Supplement_1): 1286.

https://doi.org/10.1182/blood-2019-123420

Published: 2019

Journal Articles

High Rate of Exclusion of HIV Infected Patients from Modern Lymphoma Studies: An Analysis of Current United States Therapeutic Trials

Manoj P. Menon, MD, Victor A. Chow, MD, Adam Greenbaum, MD PhD, Ryan C. Lynch, MD, Mazyar Shadman, MD MPH, Andrei Shustov, MD, Stephen D. Smith, MD, Brian G. Till, MD, Yolanda D. Tseng, MD, Chaitra S. Ujjani, MD, Thomas S. Uldrick, MD MS, Edus H. Warren, MD PhD, Ajay K. Gopal, MD

Blood (2019) 134 (Supplement_1): 4733.

https://doi.org/10.1182/blood-2019-127505

Published: 2019

Journal Articles

Long-Term Follow-up of Idelalisib Monotherapy in Patients with Double-Refractory Marginal Zone Lymphoma or Lymphoplasmacytic Lymphoma/ Waldenstrom's Macroglobulinemia

Nina D. Wagner-Johnston, MD, Stephen J. Schuster, MD, Sven de Vos, MD PhD, Gilles A. Salles, MD PhD, Wojciech Jurczak, MD PhD, Nishan Rajakumaraswamy, MD, Guan Xing, PhD, Ajay K. Gopal, MD

Blood (2019) 134 (Supplement_1): 4006.

https://doi.org/10.1182/blood-2019-121936

Published: 2019

Journal Articles

A Pilot Trial of Adriamycin, Pembrolizumab, Vinblastine and Dacarbazine (APVD) for Patients with Untreated Classical Hodgkin Lymphoma

Ryan C. Lynch, MD, Chaitra S. Ujjani, MD, Edus H. Warren, MD PhD, David M. Kurtz, MD PhD, Hilary Coye, PA-C, Jacquelin Vandermeer, BS, Hongyan Du, MD, Adam Greenbaum, MD PhD, Ajay K. Gopal, MD

Blood (2019) 134 (Supplement_1): 5299.

https://doi.org/10.1182/blood-2019-124997

Published: 2019

Journal Articles

Androgen Receptor Targeting with Enzalutamide for Mantle Cell Lymphoma: Safety and Efficacy

Victor A. Chow, MD, Paul S. Martin, MD, Stephen D. Smith, MD, Brian G. Till, MD, Solomon A. Graf, MD, Kerstin L. Edlefsen, MD, Lindsay M. Hannan, MD MSPH, Elahe A. Mostaghel, MD PhD, Ajay K. Gopal, MD

Blood (2019) 134 (Supplement_1): 5254.

https://doi.org/10.1182/blood-2019-125462

Published: 2019

Journal Articles

A Phase 2 Study of TAK-659, an Investigational Reversible Dual SYK/FLT3 Inhibitor, in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Tycel J. Phillips, MD, Gilles Salles, MD PhD, Daniel J. Landsburg, MD, Giuseppe Gritti, MD PhD, Krish Patel, MD, Herve Tilly, MD PhD, Catherine Thieblemont, MD PhD, William Townsend, MRCP,MDFRCPath, Silvia Ferrari, MD, Kate F. Stumpo, BA, Shilpi Katyayan, Cheryl Li, Harry Miao, MD, Igor Proscurshim, Ajay K. Gopal, MD

Blood (2019) 134 (Supplement_1): 5310.

https://doi.org/10.1182/blood-2019-125650

Published: 2019

Journal Articles

Phase II Window Study of Pembrolizumab in Untreated B-Cell Non-Hodgkin Lymphoproliferative Diseases

Ajay K. Gopal, MD, Adam Greenbaum, MD PhD, Ryan C. Lynch, MD, Edus H. Warren, MD PhD, Chaitra S. Ujjani, MD, Mazyar Shadman, MD, Stephen D. Smith, MD, Brian G. Till, MD, Jonathan R. Fromm, MD PhD, Andrei R Shustov, MD, Qian Vicky Wu, PhD, Manoj P. Menon, MD

Blood (2019) 134 (Supplement_1): 5258.

https://doi.org/10.1182/blood-2019-124984

Published: 2019

Journal Articles

A Window Study of Ixazomib in Untreated B-NHL

Solomon A. Graf, MD, Ryan C. Lynch, MD, Chaitra S. Ujjani, MD, David G. Coffey, MD, Andrew J. Cowan, MD, Stephen D. Smith, MD, Mazyar Shadman, MD, Edus H. Warren, MD PhD, Edward N. Libby, III, MD, Colin D. Godwin, MDMPhil, Ryan D. Cassaday, MD, Ted A Gooley, PhD, Jonathan R. Fromm, MD PhD, Ajay K. Gopal, MD

Blood (2019) 134 (Supplement_1): 5260.

https://doi.org/10.1182/blood-2019-126153

Published: 2019

Journal Articles

Ibrutinib Selects for Cells with Elevated Reactive Oxygen Species and Downregulated Phosphatases

Nathan Camp, PhD, Meghan Garrett, Ajay K. Gopal, MD, Richard James, PhD

Blood (2019) 134 (Supplement_1): 3795.

https://doi.org/10.1182/blood-2019-124454

Published: 2019

NARROW

Preliminary Results of a Phase 1 Dose Escalation Study of the First-in-Class IgM Based Bispecific Antibody Igm-2323 (anti-CD20 x anti-CD3) in Patients with Advanced B-Cell Malignancies

Pembrolizumab with R-CHOP in Previously Untreated Diffuse Large B-Cell Lymphoma: Long Term Follow up and Analysis of the Mechanism of Pdl-1 Tumor Expression

Ibrutinib and Venetoclax in Relapsed and Refractory Follicular Lymphoma

Predictors of Cytopenia after Treatment with Axicabtagene Ciloleucel in Patients with Large Cell Lymphoma

Dose-Dense Brentuximab Vedotin Plus Ifosfamide, Carboplatin, and Etoposide (ICE) Is Highly Active for Second Line Treatment in Relapsed/Refractory Classical Hodgkin Lymphoma: Final Results of a Phase I/II Study

Ixazomib-Rituximab in Untreated Indolent B-NHL: An Effective, Very Low Toxicity Regimen

Third Generation CD20 Targeted CAR T-Cell Therapy (MB-106) for Treatment of Patients with Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma

Low Achievement of End of Life Quality Measures in Large B-Cell Lymphoma Patients Who Progressed after CD19-Specific CAR-T Cell Therapy

Ibrutinib in Relapsed or Refractory Transformed Indolent B-Cell Non-Hodgkin Lymphoma: Final Results from a Prospective Phase II Study

Diffuse Large B-Cell Lymphoma Is Infiltrated with Functional CD8 + T-Cells Lacking the Hallmarks of Exhaustion

Impact of Lab Abnormalities at the Time of Progression in Patients Receiving CD19-Specific CAR T-Cell Therapy for Relapsed/Refractory Large B-Cell Lymphomas

AG-636 for the Treatment of Adults with Advanced Lymphoma: Initiation of a Phase 1 Clinical Study

High Rate of Exclusion of HIV Infected Patients from Modern Lymphoma Studies: An Analysis of Current United States Therapeutic Trials

Long-Term Follow-up of Idelalisib Monotherapy in Patients with Double-Refractory Marginal Zone Lymphoma or Lymphoplasmacytic Lymphoma/ Waldenstrom's Macroglobulinemia

A Pilot Trial of Adriamycin, Pembrolizumab, Vinblastine and Dacarbazine (APVD) for Patients with Untreated Classical Hodgkin Lymphoma

Androgen Receptor Targeting with Enzalutamide for Mantle Cell Lymphoma: Safety and Efficacy

A Phase 2 Study of TAK-659, an Investigational Reversible Dual SYK/FLT3 Inhibitor, in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Phase II Window Study of Pembrolizumab in Untreated B-Cell Non-Hodgkin Lymphoproliferative Diseases

A Window Study of Ixazomib in Untreated B-NHL

Ibrutinib Selects for Cells with Elevated Reactive Oxygen Species and Downregulated Phosphatases

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only